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BRIEF REPORT
Prevalence of carbapenem resistant Enterobacteriaceae from a tertiary care 
hospital in Mumbai, India
Pravin K. Nair, Michelle S Vaz
Holy Spirit Hospital, Department of Clinical Microbiology, Mumbai, India
ABSTRACT
Objective: The emergence of Carbapenem Resistant Enterobacteriaceae (CRE) in recent times has become a serious 
threat to public health due to the high mortality, potential dissemination rates and limited treatment options associated 
with these organisms. Thus, the present study was conducted in our tertiary care hospital in Mumbai, to retrospectively 
analyze the prevalence of CRE in the hospital. 
Methods: The study was carried out in the microbiology department of the tertiary care hospital over a period of 12 
months. The samples tested were clinical samples from hospitalized and Out-Patient Department (OPD) patients sent to 
the department for microbiological testing. CRE isolates were identified using the Vitek 2- Compact system (BioMérieux, 
France).
Results: A CRE prevalence rate of 12.26% was obtained from the study, from which the majority of the isolates were 
detected in urine samples (46%). Although most of the CRE isolates were detected in patient samples from the wards 
(42%) and the ICU (26%), a significant number of isolates was also detected from the OPD patients (19%).
Conclusion: Thus, the study shows a significant rate of carbapenem resistance among Enterobacteriaceae isolated from 
hospitalized and OPD patients. This emphasizes the urgent need for CRE control at the hospital and community level, 
and to rationalize the use of antibiotics. J Microbiol Infect Dis 2013;3(4): 207-210
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Bombay’da bir üçüncü basamak hastanede Karbapenem dirençli Enterobacteriaceae sıklığı
ÖZET
Amaç: Karbapenem dirençli Enterobacteriaceae (CRE) enfeksiyonlarındaki artış halk sağlığı için önemli bir tehdit oluştur-
maktadır çünkü bu bakterilerin enfeksiyonlarında kullanılabilecek sınırlı sayıda antibiyotik vardır ve mortalitesi yüksektir. 
Bu çalışma, Mumbai’de bulunan üçüncü basamak hizmet veren merkezimizde CRE prevalansını belirlemek amacıyla 
retrospektif olarak yapıldı.
Yöntemler: Çalışma mikrobiyoloji bölümünde 12 aylık bir sürede yapıldı. Hem hastane kökenli hem de toplum kaynaklı 
örnekler çalışmaya dahil edilmiştir. Örnekler Vitek 2- Compact System (BioMérieux, France) ile analiz edildi.
Bulgular: Çalışmamızda CRE sıklığı %12.26olarak bulunmuş olup örneklerin büyük bir kısmı idrar (% 46) örneklerinden 
elde edildi. Ancak CRE izole edilen örneklerin önemli bir kısmı yara örneklerinden (% 42) idi. Örneklerin % 26’sı yoğun 
bakım hastalarından izole edilirken %19’u da toplum kaynaklı örneklerden izole edildi. 
Sonuç: Çalışmamızda Enterobacteriaceae üyelerinin önemli bir kısmında karbapenem direnci olduğu gösterilmiştir. CRE 
kökenlerinin toplumda ve hastanede kontrol edilmesini sağlayacak önlemlere ve akılcı antibiyotik kullanımı sağlayacak 
tedbirlere ihtiyaç vardır. 
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INTRODUCTION
Carbapenems are a group of β-lactam antimicrobial 
agents with an exceptionally broad spectrum of ac-
tivity.1 They are used as a last resort against many 
multi drug resistant, gram negative bacteria, and in 
cases of infections due to Extended spectrum beta 
lactamase (ESBL) and Amp C enzyme producing 
Enterobacteriaceae.2,3 The emergence and dissem-
ination of carbapenem resistant bacteria in recent 
times represents a serious threat to public health. 
Resistance has been observed in several Entero-
bacteriaceae, as well as in members of the Pseu-
domonas and Acinetobacter genera.2 These organ-
isms are associated with high mortality rates and 
have the potential to spread widely.4
Resistance  to  carbapenems  can  be  brought 
about by various mechanisms, the most common 
being the production of carbapenemases, a class of 
enzymes capable of hydrolyzing carbapenems and 
other β-lactams.3 Resistance to carbapenems can 
also be due to the poor binding of carbapenems to 
penicillin-binding  proteins present in the bacteria, 
the over-expression of multidrug efflux pumps by 
the bacteria or lack of porins present in the bacterial 
cell membrane. However, for significant resistance 
to emerge, it is thought that a combination of resis-
tance mechanisms is required.5
Carbapenem  Resistant  Enterobacteriaceae 
(CRE) can be defined as Enterobacteriaceae that 
are resistant to one or all of the following carbapen-
ems: ertapenem, meropenem, imipenem or doripe-
nem; and resistant to all of the following third-gener-
ation cephalosporins: ceftriaxone, cefotaxime, and 
ceftazidime.  Klebsiella  species  and  Escherichia 
coli that meet the CRE definition are a priority for 
detection; however, other Enterobacteriaceae (e.g. 
Enterobacter species) are also of significant impor-
tance. CRE have been associated with high mortal-
ity and morbidity rates of up to 40-50% recorded in 
some studies.4 Also, CRE are found to carry genes 
that confer high levels of resistance to many other 
antimicrobials, often leaving very limited therapeutic 
options.4,6
In 2007, the overall worldwide susceptibility to 
carbapenems was 98% among the Enterobacteria-
ceae. Presumably this is caused due to a number of 
factors, including antibiotic usage, dosing regimens, 
and local hospital practices concerning isolation of 
patients with multiresistant pathogens.7 With the in-
creasing incidence of CRE in hospitals, a rapid and 
accurate  routine  protocol  for  CRE  screening  and 
detection is required. Appropriate detection of CRE 
is vital in patient care and infection control in order 
to institute correct, targeted treatment and to reduce 
the escalation of resistance.3
The  primary  objective  of  this  study  was  to 
evaluate the prevalence of CRE in a 330 bedded 
tertiary care hospital in Mumbai. This study is epi-
demiologically important since studies based on the 
emergence and spread of carbapenem resistance 
in India, are very limited, of which studies pertaining 
to CRE specifically are even fewer. 
METHODS
The study was a retrospective study carried out in 
the Microbiology department of a tertiary care hos-
pital,  Mumbai,  from  January  2012  to  December 
2012. The clinical samples tested were those col-
lected from patients hospitalized in the wards, the 
Intensive Care Unit (ICU), the Cardiac Care Unit 
(CCU), the Neonatal Intensive Care Unit (NICU), 
the Pediatric Intensive Care Unit (PICU), as well as 
from OPD patients coming to the hospital for treat-
ment. These included blood, urine, stool, endotra-
cheal secretions, sputum, pus, wound, and other 
samples. All samples were processed as per stan-
dard microbiology protocol. The identification and 
antibiotic susceptibility study of all clinical isolates 
was done using the Vitek 2 Compact System (Bio-
Mérieux,  France).  Isolates  that  showed  elevated 
MICs to one or all of the following carbapenems- 
meropenem, imipenem and ertapenem; as well as 
resistance  to ceftriaxone,  cefotaxime  and  ceftazi-
dime were considered to be carbapenem resistant. 
The resistance breakpoints used for detecting car-
bapenem  resistance  among  Enterobacteriaceae 
was  ≥4µg/ml  for  imipenem  and  meropenem,  and 
≥2µg/ml for ertapenem. The resistance breakpoints 
used for ceftriaxone and cefotaxime was ≥64µg/ml 
and for ceftazidime was ≥32 µg/ml. All resistance 
breakpoints  were  according  to  CLSI  guidelines 
(document M100-S22).3,4,6
RESULTS
A total of 1282 bacterial isolates were obtained from 
the clinical samples tested over 12 months, of which 
465 were Enterobacteriaceae. 57 isolates of the to-
tal 465 Enterobacteriaceae were found to be car-
bapenem resistant (12.26%). 
The CRE isolates obtained are given in Table 1.
The area wise distribution of CRE identified from 
the samples in the hospital is given in Fig. 1, and 
the sample wise distribution is given in Fig. 2.Nair P. K, et al. Carbapenem resistant Enterobacteriaceae from a tertiary hospital 209
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Figure 1. Area wise Distribution of CRE Isolates
Figure 2. Sample wise Distribution of CRE Isolates
Table 1. Strain and sample distribution of Carbapenem Resistant Enterobacteriaceae isolates
ICU/CCU Ward NICU/PICU OPD
Sample E. coli Klebsiella sp. E. coli Klebsiella sp. Enterobacter sp. E. coli Klebsiella sp. Enterobacter sp. E. coli Klebsiella sp. Enterobacter sp.
Blood 1 - - - - - 1 1 - - -
Sputum - 3 - 1 - - - - - - -
Urine 7 - 8 3 - - - - 7 1 -
Stool - - 1 - - 1 - - - - -
Pus/
Abscess
2 - 3 3 - - - - - - 1
ET
secretion
1 1 - - - - - - - - -
Wound - - 1 1 1 - 1 - 1 1 -
Other 1 1 - 1 1 - 1 - - - -
DISCUSSION
The prevalence of CRE in the hospital was found to 
be 12.26%. This is similar to the CRE prevalence 
rates obtained in similar studies from other parts of 
India. Datta et al. reported a CRE prevalence rate 
of 7.87% from a study conducted in a tertiary care 
hospital in North India3 while Gupta et al reported 
carbapenem  resistance  varying  from  17  to  22% 
among Enterobacteriaceae strains.8 Wattal et al re-
ported a high CRE prevalence rate ranging from 13 
to 51% in a tertiary care hospital in Delhi.9 Thus, the 
significant CRE prevalence rates recorded in differ-
ent parts of India emphasize the need for controlling 
the further dissemination of CRE. Of the CRE iden-
tified in the hospital, maximum were from patient 
urine  samples  (46%).  In  addition,  although  most 
CRE isolates were obtained from patients admitted 
in the hospital wards (42%) and ICU (26%), a sig-
nificant number of CRE isolates were also isolated 
from  OPD  patient  samples  (19%). This  suggests 
that several CRE isolated in the study may have 
been community acquired.
Enterobacteriaceae  majorly  contribute  to  the 
intrinsic human gut flora. They are also capable of 
colonizing the gut of patients and spreading through 
the community via the faeco-oral route. Thus the 
spread of CRE is deeply disconcerting in a coun-
try such as India with a reservoir of more than 1.4 
billion people.2,10 The first step in dealing with the 
problem of CRE is the identification of infected pa-
tients. Appropriate detection of CRE is vital in pa-
tient care and infection control in order to institute 
correct, targeted treatment and to reduce the esca-
lation of resistance. Although molecular techniques 
are regarded as the gold standard for detection of 
carbapenem  resistance,  it  becomes  impractical 
in a routine diagnostic laboratory setup up due to 
cost factors. Thus, the need of the hour is the rapid, 
practical and cost effective phenotypic detection of 
CRE.3  CRE  infected  patients  serve  as  reservoirs 
for spreading infection and contaminating the en-
vironment. Thus, identified CRE infected/ colonised 
patients  must  be  contact  isolated.11  Antimicrobial 
stewardship may be the most effective in the control 
of CRE through targeted specific antimicrobial us-
age. Limited use of invasive procedures is also an Nair P. K, et al. Carbapenem resistant Enterobacteriaceae from a tertiary hospital 210
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important intervention in CRE prevention in hospital 
settings.12
The major limitation of our study was the lack 
of a confirmatory test for the carbapenem resistant 
Enterobacteriaceae  identified  by  the  Vitek  2  sys-
tem. However, since this was a retrospective study 
of a routine diagnostic lab, the ability of the Vitek 2 
system to identify >90% of Enterobacteriaceae that 
are resistant to or that have reduced susceptibility 
to one or more carbapenems was considered suf-
ficient.13 
In conclusion, this study shows a significant rate of 
carbapenem resistance among Enterobacteriaceae 
isolated from hospitalized and OPD patients as re-
ported in similar studies from other parts of India. It 
provides a clearer picture of the current CRE sce-
nario in the hospital setup of the country and thus 
further emphasizes the need for control of CRE dis-
semination within the community. The need of the 
hour would be to have a strong antimicrobial stew-
ardship program, which is followed by all concerned 
Doctors, with further emphasis on better cost effec-
tive, logical infection control measures to prevent 
the dissemination of such multidrug resistant bacte-
ria. Would Antibiotic holiday, i.e. stopping the use of 
certain carbapenems, bring back organism sensitiv-
ity is another approach to be looked into.
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